Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab in frail and elderly patients with metastatic NSCLC
2016-003963-20Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Jan 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AIO-Studien. Primary endpoint: Rate of treatment-related Grade III/IV adverse events. Started Jan 2017; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-003963-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003963-20.